Cambiogenplasmid
(Redirected from Neovasculgen)
| Gene therapy | |
|---|---|
| Target gene | VEGF |
| Vector | Plasmid |
| Clinical data | |
| Trade names | Neovasculgen |
| Other names | Pl-VEGF165 |
| Routes of administration | Intraneural injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF).[1][2] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.[3][4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.
References
- ^ Lua error in Module:Citation/CS1/Configuration at line 2083: attempt to index a boolean value.
- ^ Lua error in Module:Citation/CS1/Configuration at line 2083: attempt to index a boolean value.
- ^ Lua error in Module:Citation/CS1/Configuration at line 2083: attempt to index a boolean value.
- ^ Lua error in Module:Citation/CS1/Configuration at line 2083: attempt to index a boolean value.
See also
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |